Sonnet Biotherapeutics Holdings Alpha and Beta Analysis
| SONNDelisted Stock | USD 1.26 1.90 60.13% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Sonnet Biotherapeutics Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Sonnet Biotherapeutics over a specified time horizon. Remember, high Sonnet Biotherapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Sonnet Biotherapeutics' market risk premium analysis include:
Beta (1.12) | Alpha (3.69) | Risk 17.09 | Sharpe Ratio (0.22) | Expected Return (3.76) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Sonnet |
Sonnet Biotherapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Sonnet Biotherapeutics market risk premium is the additional return an investor will receive from holding Sonnet Biotherapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Sonnet Biotherapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Sonnet Biotherapeutics' performance over market.| α | -3.69 | β | -1.12 |
Sonnet Biotherapeutics Fundamentals Vs Peers
Comparing Sonnet Biotherapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sonnet Biotherapeutics' direct or indirect competition across all of the common fundamentals between Sonnet Biotherapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sonnet Biotherapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sonnet Biotherapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Sonnet Biotherapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sonnet Biotherapeutics to competition |
| Fundamentals | Sonnet Biotherapeutics | Peer Average |
| Return On Equity | -7.15 | -0.31 |
| Return On Asset | -2.24 | -0.14 |
| Operating Margin | (14.06) % | (5.51) % |
| Current Valuation | 8.35 M | 16.62 B |
| Shares Outstanding | 6.83 M | 571.82 M |
| Shares Owned By Insiders | 4.24 % | 10.09 % |
| Shares Owned By Institutions | 9.95 % | 39.21 % |
Sonnet Biotherapeutics Opportunities
Sonnet Biotherapeutics Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Sonnet Biotherapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Sonnet or other delisted stocks. Alpha measures the amount that position in Sonnet Biotherapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Sonnet Biotherapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Sonnet Biotherapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sonnet Biotherapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Sonnet Biotherapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Sonnet Biotherapeutics. Please utilize our Beneish M Score to check the likelihood of Sonnet Biotherapeutics' management manipulating its earnings.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Build Portfolio with Sonnet Biotherapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Sonnet Stock
If you are still planning to invest in Sonnet Biotherapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sonnet Biotherapeutics' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |